Harbour Investments Inc. Buys 3,074 Shares of Eli Lilly and Company $LLY

Key Points

• Harbour Investments Inc. increased its stake in Eli Lilly and Company by 24% during the 2nd quarter, now holding a total of 15,858 shares valued at approximately $12.36 million.
• Institutional investors own 82.53% of Eli Lilly's stock, indicating strong interest from large investment firms.
• Recent earnings reports show that Eli Lilly topped analysts' expectations with $6.31 EPS for the quarter and a revenue increase of 37.6% year-over-year, leading to revised price targets from several brokerages.

Harbour Investments Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 24.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 15,858 shares of the company's stock after purchasing an additional 3,074 shares during the period. Harbour Investments Inc.'s holdings in Eli Lilly and Company were worth $12,362,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. WestEnd Advisors LLC grew its holdings in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter valued at about $27,000. Citizens National Bank Trust Department grew its holdings in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company during the first quarter valued at about $40,000. Finally, TD Capital Management LLC grew its holdings in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares during the period. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $812.65 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $769.14 billion, a P/E ratio of 53.11, a P/E/G ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The business's 50-day moving average is $744.36 and its 200 day moving average is $765.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the previous year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LLY. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. UBS Group lowered their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the company a "buy" rating in a research report on Friday, October 10th. Morgan Stanley lowered their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research report on Friday, October 3rd. Finally, JPMorgan Chase & Co. lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $948.06.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.